Papa Medical is a California-based manufacturer and seller of hemp-derived cannabinoid vaping products. The company's core product is hemp cannabinoid e-vapors — vape devices and e-liquids containing cannabinoids derived from hemp, primarily Delta-8 THC — which account for roughly 83% of revenue. Papa Medical also sells conventional nicotine vapes, medical nebulizers, and a small amount of candy and raw e-liquid materials. The company operates primarily on a B2B basis, selling products on an ODM (original design manufacturer) basis, meaning other hemp vapor brands sell Papa Medical's products under their own names. Papa Medical also sells directly to consumers via Amazon. The company manufactures in-house at its California facility, handling formulation, e-liquid production, and filling internally, and outsources some R&D and business support to a related party in China controlled by its CEO. Gross margins run around 24%, reflecting the commodity-like nature of vape manufacturing, with thin operating margins after Amazon platform fees and sales commissions. A near-term regulatory headwind is central to understanding the business: a 2026 federal law reclassifies Delta-8 THC as a Schedule 1 substance effective November 2026, which the company acknowledges will have a material adverse effect on revenues, as Delta-8 products account for roughly 29% of sales. Papa Medical's stated response is to expand its medical device business through subsidiary AirICU and pursue international markets, though currently over 90% of revenue comes from North America.